Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07540312

A Prospective Trial of a Variable Compression System for Moderate to Severe Irritable Bowel Syndrome

This prospective, interventional trial is intended to determine the safety and effectiveness of the Variable Compression System (VCS) device for Irritable Bowel Syndrome (IBS). This pilot study will enroll 20 subjects who will be required to wear the VCS device for a minimum of 6 hours a day and follow up at 21 days, 8 weeks, and 6 months post-device administration.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Central Florida Gastro Research, Kissimmee, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent to participate in the trial as prescribed.
  • Subjects with a weight of ≥50 kg and a body mass index between 18 and 40 kg/m2.
  • Diagnosed with IBS(C)-constipation, IBS(D)-diarrhea, or IBS(M)-mixed patients' diagnosis according to Rome Criteria (moderate to severe).

Exclusion criteria

  • Allergy to the investigational device or any components or clinically significant allergies (excluding mild seasonal allergies), in the opinion of the investigator.
  • Clinically relevant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or psychiatric disorders making implementation of the protocol or interpretation of the trial results difficult, or that would put the participant at risk by participating in the trial in the opinion of the Investigator.
  • Hospital admission or major surgery within 30 days prior to screening.
  • Pregnant, or positive urine pregnancy test.
  • Participation in any other investigational drug trial within 30 days prior to screening.
  • Participant with substance use disorder (SUD) and/or alcohol use disorder (AUD).
  • Participant who has other conditions that may affect compliance in the opinion of the investigator, or who are unable to participate in the trial on his/her own.
  • Participant with end stage organ disease.

Treatment and study plan

Variable Compression System

Device

The VCS is a wearable device that provides compression of the lower abdomen, torso support, and covers the torso in Far Infrared Radiation (FIR).

Primary outcomes

  1. Incidence of intolerable treatment-related adverse events (AEs)

    Time frame: 21 days

  2. Incidence, severity, and causal relationship of treatment-emergent AEs (TEAEs)

    Time frame: 21 days

Secondary outcomes

  1. Change in IBS-related symptoms

    Time frame: 21 days

Other outcomes

  1. Long-term impact of VCS use

    Time frame: 8 weeks, 6 months

    To assess the long-term change in IBS symptoms after utilizing VCS.

Study contacts

Contact information is provided by the study sponsor or research team.

Agim Beshiri, MD

CONTACT

[email protected]

+12623448468

Sponsors and collaborators

Lead sponsor

PGP Health

Industry

Registry information

Official study title

A Prospective Interventional Trial With a Non-invasive Variable Compression System (VCS) to Determine the Efficacy in Patients With Moderate to Severe Irritable Bowel Syndrome (IBS)

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 20, 2026
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.